Citations

Showing 10 of 108162 citations.

An Evaluation of Analytic Goals for Assays of Drugs
Steele, Bernard W., Wang, Edward , Klee, George G., Elin, Ronald J., Soldin, Steven J., Witte, David L., Richards, C. Sue

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 125 | Issue: 6 | Pages: 729-735

10.5858/2001-125-0729-aeoagf | PMID 11371222 Get It

Abstract Objective.—To determine if the levels of imprecision of the commonly used analytic methods for drug measurements are suitable for long-term therapeutic drug monitoring. Design.—In 1996, 4 identical lyophilized samples (2 in the first mailing and 2 in the second mailing 4 months later) were sent to laboratories participating in a nationwide proficiency testing program. Similarly, in 1999, replicates from a liquid pool of spiked sera were mailed 3 times, 4 months apart, to participating laboratories. For each of 11 drugs regulated under the Clinical Laboratory Improvement Amendments of 1988 and 1 metabolite, the total variance for each method was partitioned into within- and between-laboratory components. The total within-laboratory and the total survey coefficients of variation (CVs) for each method were then compared with the “acceptable” precision criteria of Glick, Burnett, and Fraser for each drug. Setting.—The first 2 mailings of the College of American Pathologists Therapeutic Drug Monitoring surveys for 1996, sets Z and ZM, and the 3 mailings of 1999, sets ZM, Z, and Z2. Main Outcome Measures.—For each drug studied, the CV of each method was compared with the various imprecision criteria, and if greater than any of the criteria, the method was then tabulated as not meeting that specific criterion. Participants.—The approximately 5000 participants of the survey. Results.—The number of methods deemed as not having acceptable total long-term within-laboratory precision by the various criteria ranged from 35% to 88% in 1996 and from 22% to 77% in 1999. Conclusion.—The number of failures possibly indicates that many of the reagent assays being utilized are not precise enough for long-term therapeutic drug monitoring of chronically administered drugs or that the published criteria used to evaluate the data in this study are too stringent.
Reference Laboratory Telephone Service Quality
Dale, Jane C., Novis, David A., Meier, Frederick A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 125 | Issue: 5 | Pages: 608-612

10.5858/2001-125-0608-rltsq | PMID 11300930 Get It

Abstract Objectives.—To establish the rates with which reference laboratories resolve inquiries telephoned to them from primary laboratories and to identify reference laboratory practices associated with higher rates of inquiry resolution. Design and Participants.—For 2 months, or until 50 contacts had occurred, 545 primary laboratories participating in the College of American Pathologists Q-Probes laboratory quality improvement program prospectively documented and characterized telephone inquiries they made to a reference laboratory of their choice. Participants also cataloged their own laboratory's demographic and practice characteristics and their reference laboratory's customer service characteristics. Main Outcome Measure.—Rates with which reference laboratories resolved telephone inquiries. Results.—Participants characterized 11 031 (78.7%) of 14 017 telephone inquiries as resolved by the reference laboratories. Ranked according to inquiry resolution rates, primary laboratories in the 90th percentile characterized reference laboratories as resolving 100% of their inquiries; those in the 10th percentile characterized reference laboratories as resolving only 54.2% of their inquiries. The rate of resolved inquiries was significantly higher (P = .0047) for participants using reference laboratories with 24-hour customer service than it was for participants using reference laboratories with less than 24-hour service. Most primary laboratories (80.9%) chose to monitor 1 of 11 national reference laboratories; in this subset, median rates of inquiry resolution ranged from 90.2% to 55.0% (P < .0001), despite no significant variation in other measured customer service characteristics. Conclusions.—Primary laboratories experience significant differences in the rates with which reference laboratories resolve telephone inquiries. The performance benchmark for reference laboratories is resolution of at least 90% of telephone inquiries from primary laboratory customers.
Aligning Cancer Clinical Trials With Cancer Burden
Desai, Aakash , Kuderer, Nicole M. , Desai, Aakash P , Lyman, Gary H

Mayo Clinic

JAMA Oncology | January 28, 2021 | Volume: 7 | Issue: 3 | Pages: 357

10.1001/jamaoncol.2020.7293 | PMID 33507227 Get It

Trends in Pain Medication Initiation Among Patients With Newly Diagnosed Diabetic Peripheral Neuropathy, 2014-2018
Fan, Jungwei , Jeffery, Molly M. , Hooten, W. Michael , Shah, Nilay D. , Jeffery, Molly Moore, Jeffery, Molly Moore , Fan, Jungwei , McCoy, Rozalina G.

Mayo Clinic

JAMA Network Open | January 28, 2021 | Volume: 4 | Issue: 1 | Pages: e2035632

10.1001/jamanetworkopen.2020.35632 | PMID 33507254 Get It

Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
Zhao, Yiqing , Yu, Hanzhong, Ida, Cris, Halling, Kevin C. , Kipp, Benjamin R. , Geiersbach, Katherine B. , Rumilla, Kandelaria M., Gupta, Sounak , Lin, Ming‐Tseh , Zheng, Gang , Ida, Cris M, Geiersbach, Katherine, Geiersbach, Katherine

Mayo Clinic

JAMA Network Open | January 28, 2021 | Volume: 4 | Issue: 1 | Pages: e2035479

10.1001/jamanetworkopen.2020.35479 | PMID 33507258 Get It

Primary Liposarcoma of the Liver
Nelson, Viera, Fernandes, N, Woolf, Graham M., Geller, Stephen A., Petrovic, Lydia M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 3 | Pages: 410-412

10.5858/2001-125-0410-plotl | PMID 11231494 Get It

Abstract Liposarcoma is a rare mesenchymal malignant tumor, which usually originates in the retroperitoneum and the extremities. Seven cases of primary liposarcoma of the liver have been previously reported. We present the eighth case, which occurred in an adult female patient. Primary liposarcoma of the liver, although extremely rare, must be considered in the differential diagnosis of a hepatic mass that develops in a noncirrhotic liver, especially in patients who are potential candidates for orthotopic liver transplantation. Liposarcoma is an absolute contraindication for liver transplantation.
“Congo” Red
Steensma, David P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 2 | Pages: 250-252

10.5858/2001-125-0250-cr | PMID 11175644 Get It

Abstract Context. —Congo red is the essential histologic stain for demonstrating the presence of amyloidosis in fixed tissues. To the best of my knowledge, nothing has been written about why the stain is named “Congo.” Objective. —To understand the etymology and history of the Congo red histologic stain. Design. —Primary sources were consulted extensively, including 19th-century corporate documents, newspapers, legal briefs, patents, memoirs, and scientific papers. Setting. —Sources were obtained from multiple university libraries and German corporate archives. Results. —To Europeans in 1885, the word Congo evoked exotic images of far-off central Africa known as The Dark Continent. The African Congo was also a political flashpoint during the Age of Colonialism. “Congo” red was introduced in Berlin in 1885 as the first of the economically lucrative direct textile dyes. A patent on Congo red was filed by the AGFA Corporation of Berlin 3 weeks after the conclusion of the well-publicized Berlin West Africa Conference. During these important diplomatic talks, German Chancellor Otto von Bismarck presided over a discussion of free trade issues in the Congo River basin. A challenge to AGFA's Congo red patent led to a precedent-setting decision in intellectual property law. Conclusions. —The Congo red stain was named “Congo” for marketing purposes by a German textile dyestuff company in 1885, reflecting geopolitical current events of that time.
Sources of Variability
Steele, Bernard W., Klee, George G., Elin, Ronald J., Witte, David L., Wang, Edward , Richards, C. Sue

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 2 | Pages: 183-190

10.5858/2001-125-0183-sov | PMID 11175632 Get It

Abstract Objective. —To determine the magnitudes and sources of analytic variation in testing for therapeutic drugs. Specifically, among laboratories using the same analytic method, to compare the within-laboratory variation (including both short- and long-term variation) with the between-laboratory variation. Design. —Four identical challenges were prepared from a lyophilized pool of spiked sera and were sent in pairs 4 months apart to laboratories participating in a nationwide proficiency-testing program. For each of 25 drugs, the variability in reported results from laboratories using the same method was investigated using nested analysis of variance. Setting. —The first 2 mailings of the College of American Pathologists Therapeutic Drug Monitoring Survey, 1996, sets Z and ZM. Main Outcome Measures. —For each drug, total variance was partitioned into within- and between-laboratory components for common methods. The within-laboratory component was further partitioned into short- and long-term components. Participants. —The approximately 5000 laboratories enrolled in the survey. Results. —For the 25 drugs, the average percentages of the total variance due to short-term, within-laboratory variance; long-term, within-laboratory variance; between-laboratory variance; and total laboratory variance were 25.0% (range, 8.8–50.6%), 57.8% (35.3–73.7%), 17.3% (5.0–35.4%), and 82.7% (64.6–95.0%), respectively. Conclusion. —For all drugs tested, the within-laboratory component of variance was greater than the between-laboratory component of variance. Within laboratories, the magnitude of the long-term component was generally greater than the magnitude of the short-term component. This information will be helpful in determining the clinical utility of various drug assays and in evaluating the appropriateness of regulations involving therapeutic drug testing.
Metastatic Angiosarcoma Masquerading as Diffuse Pulmonary Hemorrhage
Adem, Camilo, Aubry, Marie‐Christine, Tazelaar, Henry D. , Aubry, Marie-Christine, Tazelaar, Henry D. , Myers, Jeffrey L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 12 | Pages: 1562-1565

10.5858/2001-125-1562-mamadp | PMID 11735690 Get It

Abstract Context. —Diffuse pulmonary hemorrhage is an uncommon presenting manifestation of angiosarcoma. Objective. —To review the clinical, radiologic, and pathologic findings of patients with metastatic angiosarcoma who presented with diffuse pulmonary hemorrhage. Design. —Patients fulfilling inclusion criteria were identified from the consultation files. Clinical and radiologic data were obtained from referring pathologists. Histologic slides were reviewed in all patients. Results. —Our patients included 6 men and 1 woman, aged 31 to 73 years; 4 patients were younger than 40 years. Six patients presented with hemoptysis, and all had diffuse abnormalities on radiographic studies. Clinical considerations prior to biopsy included pulmonary hemorrhage syndrome (n = 2), acute respiratory failure (n = 1), and infection (n = 1). Metastatic disease was included in the differential diagnosis in only 1 patient. None had a diagnosis of malignancy prior to lung biopsy. All biopsies showed hemorrhage associated with atypical epithelioid and spindle cells, forming anastomosing vascular channels, distributed along and within lymphatics and arteries. Neoplastic cells were immunoreactive for factor VIII–related protein or CD31 in all cases for which special stains were available. Three patients with complete follow-up died of their disease. Primary sites were discovered in all 3 patients who underwent autopsy examination. Two tumors arose in the heart and 1 in the pelvic soft tissues. One additional patient had a likely primary site identified in the right atrium by cardiac ultrasound and was subsequently lost to follow-up. Conclusion. —Angiosarcoma should be included in the differential diagnosis of diffuse pulmonary hemorrhage, especially in young adults.
Solitary Blood Cultures
Novis, David A., Dale, Jane C., Schifman, Ron B., Ruby, Stephen G., Walsh, Molly K.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 125 | Issue: 10 | Pages: 1290-1294

10.5858/2001-125-1290-sbc | PMID 11570903 Get It

Abstract Objective. —To determine the frequency with which solitary blood culture samples were submitted to laboratories serving small hospitals and to ascertain whether certain hospital practices relating to the performance of blood cultures were associated with lower solitary blood culture rates (SBCRs). Design. —Participants in the College of American Pathologists Q-Probes laboratory quality improvement program collected data prospectively on the numbers of solitary blood culture sets from adult patients submitted to their laboratories and answered questions about their institutions' practice characteristics relating to the collection of blood culture specimens. Setting and Participants. —Three hundred thirty-three public and private institutions with a median occupied bed size of 57. Participants were located in the United States (n = 329), Canada (n = 3), and Australia (n = 1). Main Outcome Measure. —The solitary blood culture rate was defined as the number of instances in which only 1 blood culture venipuncture was performed on an individual patient during a 24-hour period divided by the total number of blood culture venipunctures that were performed during the study period. Results. —Participants submitted data on 132 778 adult patient blood culture sets. The SBCRs were 3.4% or less in the top-performing 10% of participating institutions (90th percentile and above), 12.7% in the midrange of participating institutions (50th percentile), and 42.5% or more in the bottom-performing 10% of participating institutions (10th percentile and below). In half the participating institutions, the SBCRs for inpatients were 8.3% or less and for outpatients, 22% or less. Solitary blood culture rates were lower for institutions in which phlebotomists rather than nonphlebotomists routinely collected blood culture specimens, in which internal policies required drawing at least 2 blood culture sets, in which hospital personnel contacted clinicians when their laboratories received requests for solitary blood culture sets, and in which quality control programs monitored SBCRs routinely. Conclusions. —Hospitals can achieve SBCRs under 5%. Those hospitals with particularly high SBCRs may lower their rates by altering certain institutional practices.